Tascom Co Ltd

Tascom Co Ltd has a negative equity position of -KRW 1,179,778,190 and a debt-to-equity ratio of -1.95, indicating a highly leveraged capital structure with liabilities exceeding assets. The company's liquidity position is further constrained by a current ratio of 0.72, suggesting that current liabilities outweigh current assets. The negative operating cash flow of -KRW 1,118,000,470 and free cash flow of -KRW 1,618,512,980 highlight significant cash outflows, which could limit the company's ability to fund operations or reduce debt. Profitability metrics show a return on equity of 1.4399, which is positive but likely driven by negative equity rather than strong earnings performance. The return on assets of -0.7887 indicates that the company is not generating returns from its asset base. These metrics are below the industry norms for medical equipment and supplies, where positive returns on equity and assets are typically expected. Tascom Co Ltd's revenue is concentrated in a single business segment focused on diabetes and pancreas care products, with no disclosed geographic diversification. This concentration increases exposure to market-specific risks, such as regulatory changes or shifts in demand for diabetes care products. The company's revenue of KRW 2,310,645,150 is in decline, with no clear growth trajectory indicated in the outlook. The negative operating income of -KRW 1,866,034,790 and net income of -KRW 1,698,775,040 suggest ongoing operational challenges. The capital expenditure of -KRW 40,818,940 indicates minimal investment in growth or capacity expansion. The risk assessment highlights medium liquidity risk and low dilution risk, but the key flag of negative net cash after subtracting total debt underscores the company's financial instability. The dilution potential is low, but the company's negative equity and high debt levels could necessitate future equity raises, which would dilute existing shareholders. Recent events include the company's transition from YidoBio Inc to Tascom Co Ltd, with a focus on medical instruments and diabetes care products. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or financial health.